12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Illumina, Roche deal

Illumina said its board unanimously rejected an unsolicited tender offer from Roche to acquire the sequencing and microarray company for $44.50 per share, or about $5.7 billion in cash. The board called the...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >